Cited by 257Olfactory and Sensory Function StudiesParkinson's Disease Mechanisms and TreatmentsAlzheimer's disease research and treatments

The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases

Open access
Rey, Nolwen L., Wesson, Daniel W., Brundin, Patrik·2018·Neurobiology of Disease

Abstract

Olfactory deficits are present in numerous neurodegenerative disorders and are accompanied by pathology in related brain regions. In several of these disorders, olfactory disturbances appear early and are considered as prodromal symptoms of the disease. In addition, pathological protein aggregates affect olfactory regions prior to other regions, suggesting that the olfactory system might be particularly vulnerable to neurodegenerative diseases. Exposed to the external environment, the olfactory epithelium and olfactory bulb allow pathogen and toxin penetration into the brain, a process that has been proposed to play a role in neurodegenerative diseases. Determining whether the olfactory bulb could be a starting point of pathology and of pathology spread is crucial to understanding how neurodegenerative diseases evolve. We argue that pathological changes following environmental insults contribute to the initiation of protein aggregation in the olfactory bulb, which then triggers the spread of the pathology within the brain by a templating mechanism in a prion-like manner. We review the evidence for the early involvement of olfactory structures in neurodegenerative diseases and the relationship between neuropathology and olfactory function. We discuss the vulnerability and putative underlying mechanisms by which pathology could be initiated in the olfactory bulb, from the entry of pathogens (promoted by increased permeability of the olfactory epithelium with aging or inflammation) to the sensitivity of the olfactory system to oxidative stress and inflammation. Finally, we review changes in protein expression and neural excitability triggered by pathogenic proteins that can promote pathogenesis in the olfactory bulb and beyond.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.nbd.2016.12.013

Cites

510 of 511 references verified1 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Olfactory impairment is an early predictor of Parkinson's disease development due to α-synuclein aggregation in the olfactory bulb.

    “It is worthwhile noting that olfactory impairment is an early predictor of Parkinson’s disease development due to α-synuclein aggregation in the olfactory bulb [142].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

8 of the 519 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Del Tredici K Braak H 2014 Idiopathic Parkinson’s Disease: Staging an α-Synucleinopathy with a Predictable Pathoanatomy [WWW Document] NCBI Bookshelf (URL http://www.ncbi.nlm.nih.gov/books/NBK6077/ (accessed 10.21.14))

Cited by

Sorted by citations

Authors
Rey, N. L., Wesson, D. W., & Brundin, P.
Affiliations
  • Van Andel Institute (US)
  • University of Florida (US)
Corresponding author
Rey, Nolwen L.
Venue
Neurobiology of Disease
Publisher
Elsevier BV
Published
2018-01
Volume
109
Issue
Pt B
Pages
226-248
ISSN
0969-9961 (ISSN-L)
OpenAlex
W2563994157
Cited by
257
References
519
Citations by year
2026: 19 · 2025: 20 · 2024: 14 · 2023: 31 · 2022: 21 · 2021: 44 · 2020: 50 · 2019: 24 · 2018: 18 · 2017: 15
FWCI
11.86
Type
journal article
Language
en
Open access
Locations
  • Neurobiology of Disease (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
  • HAL (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Michael J. Fox Foundation for Parkinson's Research
  • Van Andel Research Institute
  • Teva Pharmaceutical Industries
  • Tennessee Foundation
  • National Institutes of Health
  • National Institute on Deafness and Other Communication Disorders (R01DC014443, R01DC016519)
Topics
  • Life Sciences › Neuroscience › Sensory Systems › Olfactory and Sensory Function Studies
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Keywords
olfactory bulb, prion-like propagation, neurodegenerative diseases, olfactory dysfunction, olfactory epithelium, protein aggregation, oxidative stress, neuroinflammation, neuronal excitability, prodromal symptoms
MeSH terms
Animals, Olfaction Disorders, Humans, Olfactory Bulb, Olfactory Mucosa, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review